Healthcare · NSE: TORNTPHARM
Intrynsic's multi-model valuation estimates Torrent Pharmaceuticals Limited's fair value at ₹1,945 per share (range ₹1,945–₹2,119) against a market price of ₹4,669 (close of 17 Nov 2026): the estimate is 58% below the price. Estimate updated 17 November 2026. This is an estimated fair value based on stated assumptions, not investment advice.
Market price
₹4,669
close of 17 Nov 2026
Est. fair value
₹1,945
₹1,945–₹2,119
Estimate vs price
-58.4%
estimate below price
Above fair-value est.
Torrent Pharmaceuticals makes branded generic medicines, mainly for India, Brazil and Germany, with strength in heart and diabetes drugs. Growth in its Indian branded portfolio drives most of its profit.
FY26
FY26
FY26
FY26
Over the last 3 years, revenue grew 13.3%/yr and profit grew 19.8%/yr. Over 9 years, revenue grew 10.2%/yr and profit 9.6%/yr.
Every ₹100 of shareholder money earned ₹25.5 in profit last year, vs a sector median of 10.2%.
Debt is 1.79x shareholder equity and 3.0x yearly operating earnings — a heavy load.
The market price is above our estimated fair-value range (based on stated assumptions).
About ₹144 of every ₹100 of reported profit turned into free cash (median, last 5 years); operating cash flow was positive in 5 of 5 years.
Intrynsic's multi-model valuation estimates Torrent Pharmaceuticals Limited's fair value at ₹1,945 per share (range ₹1,945–₹2,119), last updated 17 November 2026. This is an estimate based on stated assumptions, not investment advice.
Torrent Pharmaceuticals Limited trades at ₹4,669 against Intrynsic's estimated fair value of ₹1,945 - the market price is 58% above the estimate, i.e. above our estimated fair-value range. Different assumptions produce different estimates; see the model breakdown above.
Torrent Pharmaceuticals Limited trades at about 73.0 times its latest annual earnings per share.
Torrent Pharmaceuticals makes branded generic medicines, mainly for India, Brazil and Germany, with strength in heart and diabetes drugs. Growth in its Indian branded portfolio drives most of its profit.
Intrynsic runs 2 valuation models for Torrent Pharmaceuticals Limited (EV/EBITDA, P/E Multiple) and blends them into one estimated fair-value range. Every assumption - growth, discount rate, terminal value - is shown openly on this page.
Disclaimer: Intrynsic provides educational and informational analysis only. Fair-value figures are estimates based on stated assumptions- they are not investment advice, research recommendations, or an offer to transact in any security. The models rely on assumptions (discount rates, growth, multiples) that may prove wrong and on past financials, which do not guarantee future results; prices also move on macro factors the models don't capture. Intrynsic is not a SEBI-registered investment adviser or research analyst. Markets carry risk; please do your own research or consult a registered adviser before making investment decisions. Prices shown may be delayed end-of-day values. Terms · Privacy